STTR Phase I: Recombinant BCG as a novel immunoadjuvant for viral infections — NSF Award to ONCOSTING LLC (MD, $256,000)
The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project improves treatment of viral conditions, starting with influenza. Each year seasonal influenza infects 9–35 million individuals, causes 56,000 deaths in the U.S., and costs $87.1 billion. The proposed technology ha
| Award title | STTR Phase I: Recombinant BCG as a novel immunoadjuvant for viral infections |
|---|---|
| Award ID | 2208609 |
| Awardee | ONCOSTING LLC |
| City | BALTIMORE |
| State | MD |
| Amount obligated | $256,000 |
| Principal investigator | Todd Wallach |
| Program | STTR Phase I |
| Start date | 06/01/2022 |
| Abstract | The broader impact /commercial potential of this Small Business Technology Transfer (STTR) Phase I project improves treatment of viral conditions, starting with influenza. Each year seasonal influenza infects 9–35 million individuals, causes 56,000 deaths in the U.S., and costs $87.1 billion. The proposed technology has the potential to produce more rapid protection, expand pathogen/variant coverage, and extend the longevity of protection afforded by influenza vaccination and other vaccines. Thi |
| Source | NSF Awards |
$799/mo
Try NSFGrants →